{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:18Z","timestamp":1791472098192,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victoria Richardson, PhD"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rapidity of onset of efficacy following dose escalation of subcutaneous infliximab after loss of response remains unclear in Crohn\u2019s disease (CD) and ulcerative colitis (UC). This post hoc analysis of the LIBERTY-CD and LIBERTY-UC trials evaluated time to response recovery following dose escalation of subcutaneous infliximab after loss of response, and characterized patients who experienced early recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis included week 10 responders to intravenous infliximab induction who were randomized to receive subcutaneous infliximab 120\u2009mg every other week (Q2W) and underwent dose escalation to 240\u2009mg Q2W following loss of response. Time to response recovery was assessed, and outcomes pre-\/post-dose escalation were analyzed by recovery timing (early [\u22648\u2009weeks], late [&amp;gt;8\u2009weeks], non-recovery). Week 102 outcomes and factors associated with early recovery were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Response recovery was achieved in 85.1% (40\/47) with CD and 82.3% (51\/62) with UC, with early recovery in 66.0% (31\/47) and 69.4% (43\/62), respectively. Early recovery groups in CD and UC showed greater serum infliximab increases than late or non-recovery groups. At week 102, numerically higher rates of clinical response and clinical remission in CD, and endoscopic remission in UC, were observed in early versus late recovery group. Factors associated with early recovery differed between CD and UC: systemic inflammatory and pharmacokinetic parameters were linked to early recovery in CD, while mucosal and gut-specific factors predominated in UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dose escalation of subcutaneous infliximab led to rapid response recovery in most patients with CD and UC. Early recovery was associated with favorable long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration numbers<\/jats:title>\n                    <jats:p>NCT03945019 and NCT04205643.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag017","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:57:31Z","timestamp":1773853051000},"page":"1235-1247","source":"Crossref","is-referenced-by-count":1,"title":["Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD &amp; LIBERTY-UC trials"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C","family":"Dubinsky","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital Schleswig-Holstein, Kiel University , Kiel,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5555","authenticated-orcid":false,"given":"Andres J","family":"Yarur","sequence":"additional","affiliation":[{"name":"F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-932X","authenticated-orcid":false,"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IRCCS San Raffaele Hospital and Vita-Salute University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6954-983X","authenticated-orcid":false,"given":"Hyunseong","family":"Yu","sequence":"additional","affiliation":[{"name":"Global Medical Division, Celltrion Inc. , Incheon,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong-Hyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Global Medical Division, Celltrion Inc. , Incheon,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-4708","authenticated-orcid":false,"given":"Young Nam","family":"Lee","sequence":"additional","affiliation":[{"name":"Global Medical Division, Celltrion Inc. , Incheon,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026070620125292800_izag017-B1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B3","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070620125292800_izag017-B4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"2026070620125292800_izag017-B5","doi-asserted-by":"publisher","first-page":"jjaf060","DOI":"10.1093\/ecco-jcc\/jjaf060","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)","volume":"19","author":"Colombel","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"2026070620125292800_izag017-B7","author":"Remsima EPAR\u2014Assessment report\u2014Variation","year":"2020"},{"key":"2026070620125292800_izag017-B8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620125292800_izag017-B9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ibd\/izac200","article-title":"Systematic review and meta-analysis: loss of response and need for dose escalation of infliximab and adalimumab in ulcerative colitis","volume":"29","author":"Savelkoul","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2026070620125292800_izag017-B10","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s10620-015-3735-4","article-title":"Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis","volume":"60","author":"Taxonera","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2026070620125292800_izag017-B11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.dld.2013.10.007","article-title":"Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study","volume":"46","author":"Cesarini","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2026070620125292800_izag017-B12","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in Crohn\u2019s disease patients with loss of response","volume":"18","author":"Katz","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620125292800_izag017-B13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/jgh.16133","article-title":"Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses","volume":"38","author":"Srinivasan","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2026070620125292800_izag017-B14","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070620125292800_izag017-B15","author":"EMA","year":"2025"},{"key":"2026070620125292800_izag017-B16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/apt.16770","article-title":"Letter: treatment with subcutaneous CT-P13 in Crohn\u2019s disease patients with intravenous infliximab failure","volume":"55","author":"Caron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620125292800_izag017-B17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00384-024-04727-3","article-title":"Subcutaneous infliximab in Crohn\u2019s disease patients with previous immunogenic failure of intravenous infliximab","volume":"39","author":"Husman","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"2026070620125292800_izag017-B18","doi-asserted-by":"publisher","first-page":"24347","DOI":"10.1038\/s41598-024-75693-7","article-title":"Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"2026070620125292800_izag017-B19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070620125292800_izag017-B20","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1053\/j.gastro.2025.01.078","article-title":"Two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy\u2014from LIBERTY-CD and LIBERTY-UC","volume":"168","author":"Hanauer","year":"2025","journal-title":"Gastroentero\u00adlogy"},{"key":"2026070620125292800_izag017-B21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620125292800_izag017-B22","doi-asserted-by":"publisher","first-page":"otad040","DOI":"10.1093\/crocol\/otad040","article-title":"Subcutaneous infliximab in refractory Crohn\u2019s disease patients: a possible biobetter?","volume":"5","author":"Cerna","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026070620125292800_izag017-B23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease","volume":"18","author":"Roblin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2036.2010.04523.x","article-title":"The efficacy of shortening the dosing interval to once every six weeks in Crohn\u2019s patients losing response to maintenance dose of infliximab","volume":"33","author":"Kopylov","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620125292800_izag017-B26","doi-asserted-by":"publisher","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","article-title":"Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters","volume":"13","author":"Kim","year":"2021","journal-title":"MAbs"},{"key":"2026070620125292800_izag017-B27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.crohns.2011.07.005","article-title":"Intensification of infliximab therapy in Crohn\u2019s disease: efficacy and safety","volume":"6","author":"Chaparro","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B28","doi-asserted-by":"publisher","first-page":"jjae127","DOI":"10.1093\/ecco-jcc\/jjae127","article-title":"Subcutaneous infliximab cutoff points in patients with inflammatory bowel disease: data from the ENEIDA registry","volume":"19","author":"Iborra","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B29","doi-asserted-by":"publisher","first-page":"17562848211059954","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026070620125292800_izag017-B30","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"2026070620125292800_izag017-B31","doi-asserted-by":"publisher","first-page":"e21154","DOI":"10.1016\/j.heliyon.2023.e21154","article-title":"Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: a prospective study","volume":"9","author":"Derakhshan Nazari","year":"2023","journal-title":"Heliyon"},{"key":"2026070620125292800_izag017-B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","article-title":"Predictors of early response to infliximab in patients with ulcerative colitis","volume":"13","author":"Ferrante","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620125292800_izag017-B33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"2026070620125292800_izag017-B34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ecco-jcc\/jjy028","article-title":"Accelerated clearance of infliximab is associated with treatment failure in patients with corticosteroid-refractory acute ulcerative colitis","volume":"12","author":"Kevans","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"2026070620125292800_izag017-B36","doi-asserted-by":"publisher","first-page":"jjae151","DOI":"10.1093\/ecco-jcc\/jjae151","article-title":"Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease","volume":"19","author":"Samnani","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD bioresource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070620125292800_izag017-B38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcmgh.2022.03.003","article-title":"Interleukin 1beta blockade reduces intestinal inflammation in a murine model of tumor necrosis factor-independent ulcerative colitis","volume":"14","author":"Liso","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026070620125292800_izag017-B39","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12913-022-08683-y","article-title":"Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries","volume":"22","author":"Yoo","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2026070620125292800_izag017-B40","doi-asserted-by":"publisher","first-page":"e001105","DOI":"10.1136\/bmjgast-2023-001105","article-title":"Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)","volume":"10","author":"Carbery","year":"2023","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1235\/67391989\/izag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1235\/67391989\/izag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:12:58Z","timestamp":1783383178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/7\/1235\/8527825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag017","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,18]]}}}